knowledge -WSS

knowledge

author：leisure time 2025-10-01 01:00:05 - browse：775

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Will the IRA bring competition to the biologics market?

knowledge

WSS

Eisai exec who led development of Alzheimer’s drug to retire

IRA could hurt research into orphan drugs for rare diseases

A common UTI test for kids haunts adults as a traumatic 'nightmare'

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Food makers tried to stack nutrition panel with preferred experts

Teachers share how revamped forgiveness program helped with their student loans

entertainment

knowledge

Wikipedia

Medicare details structure of new drug price negotiation program

FDA proposes changes to key medical devices approval pathway

Affirmative action in medical school literally saved lives

Generate Biomedicines machine learning biotech raises $273M

Sports medicine is finally prioritizing gender equality

Home health providers sue Medicare over payment cuts

Drug repurposing or repositioning? The language matters

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

State Dept. review finds Biden bears some blame for Afghanistan failures

The U.S. needs a new definition of substance use “recovery”

entertainment

Diverse clinical trials: Why aren’t we there yet?

Home health providers sue Medicare over payment cuts

FDA approves updated Covid vaccines

Private equity could exacerbate cardiology's overuse problem, experts fear

Eisai exec who led development of Alzheimer’s drug to retire

Teachers share how revamped forgiveness program helped with their student loans

leisure time

knowledge

focus

hotspot